Vaxil Bio Ltd. (VXL.V)
| Previous Close | 0.0150 |
| Open | 0.0150 |
| Bid | 0.0100 x 0 |
| Ask | 0.0150 x 0 |
| Day's Range | 0.0150 - 0.0150 |
| 52 Week Range | 0.0100 - 0.0350 |
| Volume | |
| Avg. Volume | 56,390 |
| Market Cap | 2.055M |
| Beta (5Y Monthly) | -3.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireVaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA, Israel, March 04, 2024 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd. (“Vaxil” or the “Company”) (TSXV:VXL) announces that further to press release from January 10, 2024 with Copper Bullet Mines Inc., (“CBMI”), the Company has received a notice of termination of the letter of intent between the Company and CBM
- GlobeNewswire
Vaxil Bio Enters Into Letter of Intent With Copper Bullet Mines in Respect of a Proposed Reverse Takeover
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA, Israel, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd. (“Vaxil” or the “Company”) (TSXV:VXL) and Copper Bullet Mines Inc., a corporation existing under the laws of Canada (“CBMI”) are pleased to announce that they have entered into a non-binding letter of intent dated January 9, 2024 (the “LOI”),
- GlobeNewswire
Vaxil Provides Update on Research Activities and Management Changes
NESS-ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE:VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases announces the follow update on its research activities and changes in senior management. Research Update As previously announced, Vaxil, together with Prof. Ayelet David, from Ben-Gurion University of the Negev (“BGU“), demonstrated therapeutic success by prolonging the survival of mice treate
